Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to seven new employees under its 2023 Inducement Plan.

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of stock options to purchase up to 48,600 shares of common stock.

The stock options feature a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.

Argus Aug 7 session

-1.32% close to close Open Argus

Details

News Market Reaction – SNDX

In the Aug 7 session, SNDX declined 1.32%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in August 2025?

Syndax granted stock options to purchase up to 48,600 shares of common stock under its 2023 Inducement Plan.

How many employees received Syndax (SNDX) inducement awards in August 2025?

Seven new employees received inducement awards from Syndax Pharmaceuticals.

What is the vesting schedule for Syndax's (SNDX) August 2025 inducement awards?

The stock options vest over 4 years, with 25% vesting after one year and 1/48th vesting monthly over the next 36 months, subject to continued employment.

When did Syndax Pharmaceuticals (SNDX) grant these inducement awards?

Syndax granted the inducement awards on August 1, 2025.